Resultados estudio ALLELE (estudio pivotal)

Tabelecleucel for allogeneic haematopoietic cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy: a phase 3, multicentre, open-label trial (ALLELE) –
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00649-6/fulltext.